Business Context and Reporting Period
This Form 6-K filing by Evogene Ltd. covers the month of September 2022, with a report date of September 14, 2022. The filing discloses a material change in management regarding Evogene's subsidiary, Lavie Bio Ltd., an ag-biologicals company focused on microbiome-based products for food quality and agricultural productivity.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is strictly a disclosure of corporate governance changes and does not contain financial statements or performance metrics.
Material Changes
- Management Appointment: Mr. Guri Oron has been appointed as Chief Executive Officer (CEO) of Lavie Bio Ltd., effective September 18, 2022.
- Executive Background: Mr. Oron brings over 20 years of experience in deep-tech, medical device, and ag-tech sectors. His recent roles include CEO of Viridix Ltd. (precision irrigation), CEO of BlueWind Medical Ltd. (7 years), and co-founder/CEO of Cybotech Ltd.
Outlook, Risks, and Commentary
The filing contains no financial guidance, outlook, or discussion of risks and contingencies. The document focuses solely on the strategic appointment of Mr. Oron to lead Lavie Bio, highlighting his extensive background in leading technology companies from inception to market.
Key Facts for Investor Verification
- Confirm the effective date of Mr. Guri Oron's appointment as CEO of Lavie Bio (September 18, 2022).
- Verify Mr. Oron's prior executive roles at Viridix Ltd. and BlueWind Medical Ltd. as stated in the filing.
- Note that this filing does not include updated financial results; investors should refer to the most recent Form 20-F or quarterly reports for financial data.